Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response. - Abstract - Europe PMC
Relationship Between Neuroendocrine and Immune Gene Expression in Small Cell Lung Cancer | bioRxiv
Binary outcomes of enhancer activity underlie stable random monoallelic expression | eLife
Endothelial cells express NKG2D ligands and desensitize antitumor NK responses | eLife
Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response. - Abstract - Europe PMC
NK cells mediate clearance of CD8+ T cell–resistant tumors in response to STING agonists | Science Immunology
NK cells mediate clearance of CD8+ T cell–resistant tumors in response to STING agonists | Science Immunology
NK cells mediate clearance of CD8+ T cell–resistant tumors in response to STING agonists | Science Immunology
Past Projects | Inclusive MCB
Binary outcomes of enhancer activity underlie stable random monoallelic expression
Binary outcomes of enhancer activity underlie stable random monoallelic expression | eLife
Demet Sag | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
Tissue-Resident Immune Cells in Humans | Annual Review of Immunology
Molecular and Cell Biology
Past Projects | Inclusive MCB
Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response. - Abstract - Europe PMC
Binary outcomes of enhancer activity underlie stable random monoallelic expression | eLife
Binary outcomes of enhancer activity underlie stable random monoallelic expression
Endothelial cells express NKG2D ligands and desensitize antitumor NK responses | eLife
Binary outcomes of enhancer activity underlie stable random monoallelic expression | eLife
Past Projects | Inclusive MCB
Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response. - Abstract - Europe PMC
PDF) Powerful synergistic effects of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC I+ tumors
